1.Schlenk, EA, Erlen, JA, Dunbar-Jacob, J, et al. Health-related quality of life in chronic disorders: A comparison across studies using the MOS SF-36. Qual Life Res. 1998;7:57–65.
2.Global Burden of Disease Cancer Collaboration. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527.
7.Schuller, Y, Hollak, CEM, Biegstraaten, M. The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review. Orphanet J Rare Dis. 2015;10:92.
8.Marra, CA, Woolcott, JC, Kopec, JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60:1571–1582.
9.Sprangers, MA, de Regt, EB, Andries, F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol. 2000;53:895–907.
13.Brooks, R. EuroQoL: The current state of play. Health Policy. 1996;37:53–72.
14.Angelis, A, Kanavos, P, López-Bastida, J, et al. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015;15:428.
15.De Wit, GA, Busschbach, JJ, De Charro, FT. Sensitivity and perspective in the valuation of health status: Whose values count? Health Econ. 2000;9:109–126.
16.Krabbe, PF, Tromp, N, Ruers, TJ, van Riel, PL. Are patients' judgments of health status really different from the general population? Health Qual Life Outcomes. 2011;9:31.
17.Versteegh, MM, Leunis, A, Uyl-de Groot, CA, Stolk, EA. Condition-specific preference-based measures: Benefit or burden? Value Health. 2012;15:504–513.
18.López-Bastida, J, Linertová, R, Oliva-Moreno, J, et al. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. Eur J Health Econ. 2016;17(Suppl 1):99–108.
19.Chevreul, K, Gandré, C, Brigham, KB, et al. Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. Eur J Health Econ. 2016;17(Suppl 1):43–52.
20.Cavazza, M, Kodra, Y, Armeni, P, et al. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur J Health Econ. 2016;17(Suppl 1):19–29.
21.Winter, Y, Schepelmann, K, Spottke, AE, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:1473–1481.
22.Calvert, M, Pall, H, Hoppitt, T, et al. Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res. 2013;22:1231–1238.
23.Kanavos, P, Nicod, E. What is wrong with orphan drug policies? Suggestions for ways forward. Value Health. 2012;15:1182–1184.
24.Drummond, M, Towse, A. Orphan drugs policies: A suitable case for treatment. Eur J Health Econ. 2014;15:335–340.
25.Mpofu, S, Moots, R. A case of multiple sclerosis associated with rheumatoid arthritis and positive anticardiolipin antibodies. Ann Rheum Dis. 2003;62:376.
27.Dickens, C, Creed, F. The burden of depression in patients with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:1327–1330.
28.Hunter, DJ, Riordan, EA. The impact of arthritis on pain and quality of life: An Australian survey. Int J Rheum Dis. 2014;17:149–155.
29.Sidovar, MF, Limone, BL, Coleman, CI. Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: An independent validation in a randomized control cohort. Patient Relat Outcome Meas. 2016;7:13–18.
30.Kemanetzoglou, E, Andreadou, E. CNS Demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17:36.
31.Heins, MJ, Korevaar, JC, Hopman, PE, et al. Health-related quality of life and health care use in cancer survivors compared with patients with chronic diseases. Cancer. 2016;122:962–970.
32.Tordrup, D, Mossman, J, Kanavos, P. Responsiveness of the EQ-5D to clinical change: Is the patient experience adequately represented? Int J Technol Assess Health Care. 2014;30:10–19.